openPR Logo
Press release

Newly Published Visiongain Report: Global Biosimilar Monoclonal Antibodies Forecast 2018-2028

11-28-2019 10:54 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Visiongain

Your guide to your industry

Your guide to your industry

Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab.

Purchase full report or download free sample pages:
https://www.visiongain.com/report/global-biosimilar-monoclonal-antibodies-forecast-2018-2028/

The global biosimilar monoclonal antibodies market is expected to reach $5.9bn in 2023 and is estimated to grow at a CAGR of 19% from 2016 to 2028.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 204-page report you will receive 72 tables and 74 figures– all unavailable elsewhere.

The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Global Biosimilar Monoclonal Antibodies Market forecasts from 2018-2028

• Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2028 for the market segmented by compound:
• Infliximab
• Rituximab
• Abciximab
• Trastuzumab
• Adalimumab
• Bevacizumab

Global Biosimilar Monoclonal Antibodies Forecast 2018-2028

• This report also shows revenue to 2028 for individual biosimilar mAb products in the market:
• Remsima/Inflectra
• Infimab
• Reditux
• BI695500
• CT-P10
• BI695501
• FKB327
• FKB238
• Mabtas
• AcellBia
• Maball
• Clotinab
• Abcixirel
• BCD-022
• BCD-021
• Herzuma
• CANMAB/Hertraz

• Our analyses show individual revenue forecasts to 2028 for these regional and national markets:
• The US Biosimilar mAb Market
• Japanese Biosimilar mAb Market
• EU5 Biosimilar mAb Markets
• BRIC and South Korea Biosimilar mAb Markets
• Rest of the World Biosimilar mAb Market

• This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline

• Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market

Visiongain’s study is intended for anyone requiring commercial analyses for the biosimilars monoclonal antibodies market. You find data, trends and predictions.

Buy our report today Global Biosimilar Monoclonal Antibodies Forecast 2018-2028: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab.

Related Reports:

Needles Market Report 2020-2030:
https://www.visiongain.com/report/needles-market-report-2020-2030/

Medical Cyclotron Market Report 2020-2030:
https://www.visiongain.com/report/medical-cyclotron-market-report-2020-2030/

Medical Document Management Systems Market Report 2020-2030:
https://www.visiongain.com/report/medical-document-management-systems-market-report-2020-2030/

For more Pharma reports, visit our website:
https://www.visiongain.com/industries/pharma/

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Visiongain Limited
Airport House
Purley Way
Surrey
London
CR0 0XZ
United Kingdom

About Visiongain:

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Newly Published Visiongain Report: Global Biosimilar Monoclonal Antibodies Forecast 2018-2028 here

News-ID: 1873616 • Views:

More Releases from Visiongain

Can Coatings Market Research Report Up to 2031
Can Coatings Market Research Report Up to 2031
Visiongain has published a new report on Can Coatings Market Report to 2031: Segmentation by Type (Epoxy, Oleoresin, Vinyl, Phenolic, Acrylic, Polyester, Polyolefin, Additives, Other Type) Segmentation by Coating Technologies (Conventional solvent borne coatings, High-solids coatings, Waterborne coatings, Ultraviolet radiation-cured (UV-cured) coatings, Powder coatings, Other Technologies) Segmentation by Application (Food Can, Beverage Can, General Line Can, Aerosol Can, Others, Other Application) PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped,
Automatic Number Plate Recognition (ANPR) System Market Report Up to 2031
Automatic Number Plate Recognition (ANPR) System Market Report Up to 2031
Visiongain has published a new report on Automatic Number Plate Recognition (ANPR) System Market Report to 2031: Forecasts by component (Hardware, Software, Services), by type (Fixed ANPR Systems, Portable ANPR Systems), by application (Traffic Management, Law Enforcement, Electronic Toll Collection, Others). PLUS Profiles of Leading Automatic Number Plate Recognition System Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Download Exclusive Sample of Report @ https://www.visiongain.com/report/anpr-system-market/#download_sampe_div Automatic number plate
Automatic Labelling Machine Market Report Up to 2031
Automatic Labelling Machine Market Report Up to 2031
Visiongain has published a new report on Automatic Labelling Machine Market Report to 2031: Forecasts by type (Stretch Sleeve Labelers, Shrink-Sleeve Labelers, Glue-based Labelers, Others), by industry vertical (Consumer Goods, Food & Beverages, Automotive, Pharmaceuticals, Others). PLUS Profiles of Leading Automatic Labelling Machine Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Download Exclusive Sample of Report @ https://www.visiongain.com/report/automatic-labelling-machine-market/#download_sampe_div An automatic labeling machine is designed to print-and-apply labels to
Atomic Absorption Spectrometer Market Report Up to 2031
Visiongain has published a new report on Atomic Absorption Spectrometer Market Report to 2031: Forecasts by type (Х-rау Dіffrасtіоn Ѕресtrоmеtrу, Х-rау Fluоrеѕсеnсе Ѕресtrоmеtrу, Others), by application (Рhаrmасеutісаl, Mining Industry, Petrochemical Industry, Fооd & Веvеrаgе, Others). PLUS Profiles of Leading Atomic Absorption Spectrometer Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Download Exclusive Sample of Report @ https://www.visiongain.com/report/atomic-absorption-spectrometer-market/#download_sampe_div Atomic absorption spectrometer is the determination of elemental composition and is

All 5 Releases


More Releases for Biosimilar

Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.